Last reviewed · How we verify
Sucrosomial Iron
Sucrosomial iron delivers iron as a ferric hydroxide complex encapsulated in a sucrose-based matrix to improve absorption and reduce gastrointestinal side effects.
Sucrosomial iron delivers iron as a ferric hydroxide complex encapsulated in a sucrose-based matrix to improve absorption and reduce gastrointestinal side effects. Used for Iron deficiency anemia.
At a glance
| Generic name | Sucrosomial Iron |
|---|---|
| Also known as | CardioSideral, Sideral Forte, SiderAl Forte, Sideral, SiderAl Forte® |
| Sponsor | Cardiochirurgia E.H. |
| Drug class | Iron supplement |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
The sucrosomal formulation protects iron from interaction with food components and gastric pH, allowing more efficient absorption in the small intestine while minimizing local irritation. This novel delivery system enhances bioavailability compared to conventional iron salts and reduces the incidence of gastrointestinal adverse events associated with standard iron supplementation.
Approved indications
- Iron deficiency anemia
Common side effects
- Gastrointestinal disturbances (nausea, constipation, abdominal discomfort)
- Headache
- Dizziness
Key clinical trials
- Efficacy and Tolerability of Sucrosomial® Iron vs Ferric Maltol in Iron Deficient Women (PHASE4)
- Sucrosomial Vs Intravenous Iron for Preoperative Anemia (PHASE4)
- Effect of Oral sucRosomIal Iron on exerciSE Capacity and Quality of Life in Patients With Heart Failure (PHASE4)
- Sucrosom5al Iron Supplementation in Blood Donors (NA)
- Iron Deficiency Anemia in the Second and Third Trimester of Pregnancy (NA)
- Pilot Study Evaluating the Advantages of Sucrosomial® Iron Post-operative Supplementation vs Standard of Care After Cardiac Surgery (EARLY_PHASE1)
- DOSE FINDING PROSPECTIVE ANALYSIS AFTER HEART SURGERY for Sucrosomial Iron (PHASE4)
- Effects of Iron Therapy in Heart Failure With Preserved Ejection Fraction and Iron Deficiency (PREFER-HF) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sucrosomial Iron CI brief — competitive landscape report
- Sucrosomial Iron updates RSS · CI watch RSS
- Cardiochirurgia E.H. portfolio CI